Bruker Corporation vs. Cytek Biosciences, Inc. Common Stock
Bruker Corporation and Cytek Biosciences, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BRKR | CTKB | |
|---|---|---|
| Market Cap | $9.61 billion | $627.82 million |
| Revenue (TTM) | $3.50 billion | — |
| Net Income (TTM) | $-64,500,000 | — |
BRKR leads on 1 of 1 size & scale factors.
Valuation
| BRKR | CTKB | |
|---|---|---|
| Price / Book | 4.00 | — |
| Price / Sales | 2.74 | — |
BRKR and CTKB split the valuation factors evenly.
Profitability
| BRKR | CTKB | |
|---|---|---|
| Net Margin | -1.84% | — |
| Return on Equity | -2.69% | — |
BRKR and CTKB split the profitability factors evenly.
Dividend
| BRKR | CTKB | |
|---|---|---|
| Dividend Yield | 0.33% | — |
BRKR and CTKB split the dividend factors evenly.
Risk & Sentiment
| BRKR | CTKB | |
|---|---|---|
| Short Interest | 1.53% | 0.01% |
CTKB leads on 1 of 1 risk & sentiment factors.
Dig deeper: BRKR overview, BRKR financials, CTKB overview, CTKB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.